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Abstract
Hepatitis E virus (HEV) is considered an emergent source of viral hepatitis worldwide,
with an increasing burden of jaundice, liver failure, extrahepatic illnesses, and deaths in
developed countries. With the scarcity of data from efficient animal models, there are still
open-ended questions about designing new models to study pathogenesis, types, virology,
and evolution of these viruses. With an emphasis on available data and updates, there is
still enough information to understand the HEV life cycle, pathogen interaction with the
host, and the valuation of the role of vaccine and new anti-HEV therapies. However, the
World Health Organization (WHO) and the European Association for the Study of the
Liver (EASL) preferred to stress prevention and control measures of HEV infections in
animals, zoonotic transmission, and foodborne transmission. It is being reviewed that with
current knowledge on HEV and existing prevention tools, there is an excellent room for
in-depth information about the virus strains, their replication, pathogenicity, and virulence.
The current knowledge set also has gaps regarding standardized and validated diagnostic
tools, efficacy and safety of the vaccine, and extrahepatic manifestations specifically in
pregnant females, immunocompromised patients, and others. This review highlights the
areas for more research exploration, focusing on enlisted research questions based on
HEV infection to endorse the need for significant improvement in the current set of
knowledge for this public health problem.
Introduction
Hepatitis E is a liver disease caused by hepatitis E virus (HEV).1 It
is the fifth known form of hepatitis among humans and is the one of
the common causes of jaundice and acute hepatitis2 that leads to sig-
nificant human morbidity and mortality. The disease was initially
discovered in 1980s by a Russian scientist as “epidemic, non-A,
non-B hepatitis,” an infectious, waterborne illness like hepatitis
A that was common in the developing countries.3 Three years later,
the virus was visualized in stool samples using an immune electron
microscope and subsequently a viral genome was cloned and named
as HEV.4 The virus sheds in stool of infected persons and enters the
human body through intestine. It is a self-limiting virus and resolves
in 2–6 weeks, but in some cases fulminant hepatitis (acute liver fail-
ure) develops and can cause death.5 This review article on HEV will
highlight genotypes, strategies to prevent and manage, and the exis-
ting knowledge gaps.
Epidemiology and current burden of
hepatitis E
HEV infection is an evolving pathogen in industrial countries
with high prevalence in developing countries. World Health
Organization (WHO) referred HEV as one of the usual utmost
infections to cause acute hepatitis with an extensive spread
worldwide.6–8 Almost 2.3 billion people get infected with HEV,
which attributes 70 000 deaths annually.6–9
Two different epidemiological forms have been witnessed in
diverse geographical areas worldwide. These arrays are assumed to
be interrelated with the spread of HEV genotypes, modes of trans-
mission, basics of viral septicity, prevalence of disease, as well as
medical indications of the infection. According to WHO and Center
for Diseases Control (CDC), the clinical characteristics and epidemi-
ology of HEV infection are principally resolute by the prime geno-
type, in particular, hosts and the area as illustrated by two
expressions of hepatitis E infection that are associated with geo-
graphic dispersal (Table 1).1,10,11 In developing countries, the epide-
miology of HEV infection indicates low seroprevalence in people
under 15 years of age; however, it rises rapidly between the ages of
15 and 30 years. The incidence is variable among developing coun-
tries with reported outbreaks affecting thousands of people, specifi-
cally during flooding or monsoons with a mortality rate of 0.5–
3%.12 HEV in developed countries shows increase in seroprevalence
with age, with a peak between 30 and 50 years and is usually spo-
radic and affects small groups with specific food background with
doi:10.1002/jgh3.12646
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no transmission from human to human.13 In European countries,
HEV is mostly acquired through local zoonotic. Animals carrying
HEV virus, affecting human health includes pigs, boar, and dear.2
Recent data report presence of HEV 3 in dolphins in Cuba,14 and
HEV-4 in cattle in China, its presence was also documented in its
milk even after pasteurization,15 which can be a risk factor for
human transmission of this virus from domestic animals .
In recent years, “hotspots” of HEV infection have been
identified in Europe. This includes western/central Poland (sero-
prevalence 50%),16 Abruzzo, central Italy (seroprevalence
49%),17 Czech Republic (400 laboratory-confirmed cases
2015),18 western Germany (1:616 blood donors viraemic,
2015),17 Scotland (1:2481 donors viraemic, 201 642),19 the Neth-
erlands (1:600 blood donors viraemic, 2014),20 and southwest
France (incidence 3–4%).15 There are also other areas with high
levels of circulating virus, but are yet unidentified.
Virology of hepatitis E. HEV is a small, unenveloped virus
of 27–34 nm diameter with icosahedral symmetry. According to
the taxonomic classification scheme, all the HEV strains are
grouped under the Hepeviridae Family, under the genus
Orthohepevirus (A–D, 4 species) and Piscihepevirus (A, 1 spe-
cies).10,21,22 It is a highly variable virus, of which
Orthohepevirus A species take in practically HEV variants of all
mammalians with seven genotypes, out of which at least five are
of human public health interest. The different HEV genotypes
have a distinct geographical distribution. HEV-1 and HEV-2
genotypes are recognized to infect humans by causing huge
waterborne outbreaks and sporadic cases in prevalent areas and
these genotypes are prevalent in developing countries.22,23 While
genotypes HEV 3 and HEV 4 are distributed worldwide and
have the potential to infect both animals and humans.24 While
one report has documented HEV infection in humans with geno-
type HEV-7 and HEV 8,25,26 with genotype HEV-7, known to
chronically infect a liver transplant patient. Furthermore,
cynomolgus macaques were infected using HEV genotype 8 posi-
tive samples, vulnerable to both acute and chronic infection.13
The genotypes 7 and 8 are deliberated to be evolving human
pathogens and there is a need for more studies to screen for
genotype 8 in humans.26
There is one serotype of HEV spreading globally27,28 that
holds a 7.2 kb + ve sense RNA genome with single-strand and
three overlapping open-reading frames (ORFs), i.e. ORF1,
ORF2, ORF3, and ORF4 having distinctive roles. ORF1 encrypts
an un-structural polyprotein that possesses 1690 amino acids and
entails proteins vital for RNA replication, e.g. methyltransferase,
RNA helicase, RNA polymerase, papain-like cysteine protease,
and RNA-dependent (Fig. 1). Although ORF2 is one of the most
vital structural proteins for pursuing HEV vaccine development,
as it encrypts capsid (protein) with neutralizing epitopes persuad-
ing antibody making in the host and reservoirs. On the other
hand, ORF3 possess 123 amino acid and overlays with ORF2,
and encrypts a minor multifunctional protein intricate in viral
particle secretion.22,32,33 All the HEV units are susceptible to fry-
ing or boiling and become deactivated at temperatures beyond
90C just after 5 min. To entirely deactivate HEV in the food-
stuff, an internal temperature of 71C for 20 min is manda-
tory34,35 and it is reported to be vulnerable from chlorine
cleansing in water supplies and fomites.22,35 While ORF4 is
novel composed of 158 amino acids in ORF1 has newly defined
for HEV-1. HEV replication is assumed to be a part of HEV rep-
lication with many viral proteins like RdRp or helicase and host
factors such as eukaryotic elongation factor 1 isoform-1
(eEF1α1) and β-tubulin. Although the existing functional role of
ORF4 in other HEV genotypes must be studied further.36,37
Transmission of Hepatitis E. Waterborne transmission is
most common in high endemic areas with poor sanitation prac-
tices, while the zoonotic or foodborne transmission is usually
caused by the consumption of raw or undercook meat from
Table 1 Two distinct epidemiological patterns of hepatitis E infection
Characteristics Low endemic Highly endemic
Definition Confirmed HEV infection in <25% of sporadic hepatitis Waterborne outbreaks or HEV infection >25% of hepatitis
Transmission Through animal sources and blood transfusion Mainly through contaminated water sources and blood
transfusion
Areas Safe and clean drinking water supply Developing countries with frequent water contamination
Genotypes 3 and 4 1 and 2
Mortality/morbidity Low mortality and morbidity High/intermediate mortality and morbidity
Cases Asymptomatic and symptomatic acute hepatitis. Chronic
hepatitis in immunocompromised individuals
Frequent outbreaks, asymptomatic and symptomatic acute
hepatitis, acute liver failure
Effected countries North and South America, Europe, Australia, South Africa,
East Asia
Africa, Central America, South, and Central Asia
Adapted from Melgaço et al.10
Figure 1 Genomic organization of HEV showing e positive sense HEV
genomic RNA and a subgenomic RNA produced during replication of
three ORFs, which encode ORF1, ORF2, and ORF3 proteins. The scale
below shows nucleotides in thousands (Adapted from Hoofnagle
et al.,5 Chandra et al.,29 Wedemeyer et al.30 and Yamashita et al.31).
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animals infected by HEV. Industrial areas account for maximum
HEV transmissions, subsequently posing a significant public
health problem.30,38,39 The mode of HEV transmission remains
contentious, and viral infection causes are often not well known,
predominantly in intermittent cases of acute hepatitis E. As in
such cases, the infection may also be associated with the level of
populace immunity, hygienic settings, living environments, and
others dynamics.40 However, recent investigations support the
presence of three further means of HEV transmission that
includes parenteral, human to human, and perinatal transmission
although these means of transmission are less frequently
observed but with increasing evidence, it emphasizes prophylac-
tic measures for the prevention of HEV infection.38–41
In various animal studies, it has been identified that viral
replication takes approximately 7 days after inoculation in hepa-
tocytes and upsets up to 90% of hepatic cells causing clinical
damage and illness with a typical incubation period of 21 days.
As viremia occurs few days earlier to the commencement of
symptoms, followed by changes in serum transaminase levels
and fecal HEV excretion for a few weeks thereafter.42,43 Regard-
ing its pathophysiology, hepatocytes are considered as the pri-
mary site for HEV replication, but there is little evidence that
reported on extrahepatic HEV replication.44–46 The information
regarding particular receptors on hepatocytes for the binding of
HEV remains imprecise. However, many studies on in vitro liver
cell culture system of Huh-7 showed that heparin sulfate proteo-
glycans on the exterior of the cell, principally syndecans most
abundantly syndecan 1, have the potential to bind with recombi-
nant HEV ORF2 protein expressed as VLPs. Mostly identified as
a hepatotoxic virus, to some extent, HEV has been found to
reproduce in other tissues causing extrahepatic indications
including neurological, renal, and hematological problems47–50
as it enters the body by contaminated water or food via the oral
route. It is assumed that the virus makes copies inside the small
intestine’s epithelial cells and then reaches the liver, which is the
ultimate target organ. Once in the hepatocytes, the virus prolifer-
ates and initiates liver damage.51
Hepatitis E and extrahepatic
manifestations
During the last decade, HEV-associated neurological conditions
that have been reported in developing countries include Bell’s
palsy, Guillain-Barre syndrome, neuralgic amyotrophy, acute
menginoencephalitis, brachial neuritis, ataxia, encephalitis, proxi-
mal myopathy, and acute transverse myelitis.47,49,52 HEV RNA
has been detected in serum and CSF not only in acute illness but
also CNS infection was found among immunosuppressed patients
after organ transplantation.53 A study also demonstrated that cell
lines of human neuronal-derived can support HEV RNA duplica-
tion that is why it is suggested that clinicians should consider the
likelihood of HEV infection in patients with neurological disor-
ders and concurrent liver enzyme alteration.54 Other extrahepatic
complications associated with HEV includes renal involvement
like cryoglobulinemia and membrano-proliferative glomerulone-
phritis. Renal impairment has been reported in solid organ trans-
plant recipients during acute HEV infection.2 Hematologic
manifestations include autoimmune hemolytic anemia, aplastic
anemia, acute liver failure associated with pure red-cell aplasia,
severe thrombocytopenia, and cutaneous T cell lympho-
proliferative syndrome.48,55–57 Other complications reported are
acute pancreatitis, myocarditis,58 Henoch-Schönlein purpura,59
myasthenia gravis,60 thyroiditis, and Grave’s thyrotoxicosis.47
However, there is need to explore the pathological relation,
mechanisms, and effective treatment because a causal relation-
ship between these associations has not been established.
Hepatitis E virus diagnostics
The European Association for the Study of the Liver (EASL) has
suggested different methods for the diagnosis of HEV, which are
as follows.61
Laboratory diagnosis. The incubation period of HEV is
approximately 15–60 days. HEV RNA is detected in blood and
stool around 3 weeks post-infection (with viraemia lasting
approximately 3–6 weeks and shedding of virus in stool for
approximately 4–6 weeks). The first appearance occurs before
the onset of symptoms and at the time of clinical onset, biochem-
ical markers elevate with first appearance of IgM antibodies
(short lived), followed by IgG antibodies (long lasting).
Molecular analysis. Detection of HEV RNA in stool or
blood is indicative of HEV infection. In patients with suppressed
immune system and chronic HEV, anti-HEV antibodies are often
undetectable, and in such cases, NATs are the only reliable
means of diagnosis (Fig. 2). Many NAT-based assays are used
for the detection of HEV RNA in stool, serum, and plasma
samples. It includes conventional reverse transcription PCR (RT-
PCR) and nested protocols, real-time RT-PCR, and transcription-
mediated amplification methods (e.g. reverse transcription loop-
mediated isothermal amplification).62–64 The frequently used
assay methods work by targeting highly conserved regions of the
genome, in particular, the region of ORF2 that overlaps ORF3,
Figure 2 Diagnostic algorithm for HEV infection (Adapted from
European Association for the Study of the Liver.61)
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and are able to detect all four major genotypes of HEV that infect
humans.65
Antibody assays. Acute HEV infection can also be diag-
nosed by HEV NAT in combination with enzyme immunoassays
by detection of anti-HEV antibodies (IgM, IgG or both). Serolog-
ical testing alone depends upon detection of anti-IgM and
increased IgG levels, since specificity of certain assays is not
optimal and anti-HEV IgM itself is not a robust marker for diag-
nosis. Anti-HEV IgA antibodies are also used for diagnosis of
acute HEV; however, such assays are not widely available. Pres-
ence of anti-HEV IgG helps to determine past HEV infection.66
Antigen assays. Both acute and chronic infections can also
be diagnosed by detection of HEV antigen by enzyme immuno-
assays. Older versions of the antigen assays were not as sensitive
as NATs; however, newer assays offer improved and better sen-
sitivity.67 Patients with acute hepatitis E may report lower anti-
gen levels than the patients with chronic hepatitis E, with an
OD450/630 of >15 (to discriminate between patients with acute
or chronic hepatitis E).68 Moreover, HEV antigen may exist for
several months after ribavirin induced HEV RNA clearance of
chronic hepatitis E. The experimental data suggest that the pres-
ence of HEV antigen does not necessarily correlate with infec-
tious virions.68 In one recent study, it was suggested that
glycosylated forms of ORF2 are excreted in the sera of infected
patients at high levels; however, infectious virions are associated
with the much less abundant nonglycosylated form of ORF2.69
Immunohistochemistry. Immunohistochemistry for HEV
ORF2 protein can be used for histopathologic diagnosis of
hepatitis E.70
UPDATE OF HEV INFECTION CONTROL
Progress in regulation and prevention have been made to lessen
the burden of both chronic and acute HEV in prevalent and non-
prevalent countries. Additional studies are still necessary to vali-
date the prominence of preventive measures globally, with
prominence on HEV in the public health system.10,12,13,21 Pre-
vention actions differ concerning the geographical areas, the
dominating genotypes, and their route of transmission. Usually,
in low prevalence areas of HEV, the zoonotic transmission domi-
nates, so there is a need to focus on zoonotic risk and food
safety. While in areas where the outbreaks are more recurrent,
the infection transmits via unhygienic practices and poor sanita-
tion. Therefore, clean drinking water and improving the individ-
ual hygiene and sanitation of human wastes can be an effective
preventive method.32,71 Transmission of HEV through sex,
saliva, semen, sweat, and breastmilk is still unclear.61 So far, pre-
ventive measures for hepatitis E include:
• Virus inactivation is done by destroying the virus in water and
food that has to be ingested by either cooking above 90C of
temperature,10,72,73 washing the vegetables and fruits using
chlorine solutions; doing chlorine disinfection for water sup-
plies and fomites.74,75
• Taking care of sanitation, hygiene, and surveillance within the
community by treating water supplies and sewage. Moreover,
on individual approach washing hands and use of gloves to
cook food; for healthcare workers, biosafety guidelines are to
be followed, such as basics of wearing specific biosafety
clothes during epidemics and dealing with blood sampling-
related procedures during laboratory screening in the blood
bank.13,29–35,39–51,62–64,69,71–87
• To accomplish mass vaccination using safe and effective vac-
cine for vulnerable animals and the public is the need for HEV
vaccine control worldwide. WHO endorses further research on
the safety, immunogenicity, and efficacy of HEV vaccine.8
The necessity for a vaccine is related to the worldwide dis-
tribution of HEV, most in the endemic regions and clusters at
highest risks such as food workers, patients with chronic liver
disease, immunosuppressed patients, tourists to prevalent areas,
older adults with more than 60 years of age, pregnant women or
those planning pregnancy and children under the age of 2 years.
The vaccine is still not recommended globally and as a part of
Immunization Practices (ACIP) or emergency immunization.88,89
Currently, the HEV239 vaccine is the only vaccine commercially
available registered in China since 2011 (Hecolin, Xiamen
Innovax Biotech, China), but still not permitted in other coun-
tries.90 A recombinant vaccine with a three dose (at 0, 1, and
6 months) scheme administered intramuscularly offers protection
against HEV4 infection with no evidence regarding
protection against other genotypes. It is a recombinant vaccine
with 26 amino acids and an extended N terminal with E2,
another peptide from the HEV capsid protein. This vaccine
method is conceivable as HEV is antigenically well-preserved,
presents only one known serotype that was perceived to be
shielding for HEV 1–4 genotypes.91,92 The vaccine is supposed
to be effective against HEV by counteracting antibodies.
A strong T cell-dependent antibody reaction was noted in mouse
models, which was partially ascribed to two T cell epitopes sited
in the region of amino acid 533–552 on the HEV capsid peptide
after vaccination. This vaccine had showed an efficacy of 97%
for preventing episodes of symptomatic acute hepatitis,90 with its
long-term efficacy proved at follow-up.92 The vaccine’s effec-
tiveness is improved up to 90% after one dose for 1 year and
after three doses for 4.5 years. Moreover, the HEV 239 vaccine
is harmless for expectant mother and their fetuses, but there is a
lack of data for efficacy, specifically in immune-compromised
and chronic liver disease patients.90–92
Treatment recommendations
There is currently a gap in the practical availability of antiviral
drugs or interventions for the patients of chronic hepatitis E,
which is essentially characterized by RNA persevering inside the
liver of immune-compromised patients for 3 months. Afterward,
it is doubtful that patients realize unprompted viral clearance
minus therapeutic mediation.2 Currently, three treatment options
are available, although no licensed drugs are available, the
options available include lessening of immunosuppression as
the first choice, use of pegylated IFN-α (pegIFN-α) and con-
sumption of ribavirin (RBV) as a monotherapy. (Fig. 3).30,93–95
RBV monotherapy for 3–6 months or blended with pegIFN-α is
the most frequently used HEV treatment. As its effectiveness in
plummeting viral loads has been recognized by many studies
involving patients with acute and chronic infections.30,90–98
Among immunocompromised people, the administration is safe
Hepatitis E and existing knowledge gaps L Kamani et al.
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and leads to viral clearance.96,97 Moreover, data from in vitro
studies advocate that RBV has a reasonable synergistic effect
once mixed with pegIFN-α.99 Unfavorably, due to absolute tera-
togenic physiognomies, RBV is not recommended for pregnant
women. Although there are quite a few approaches of action
anticipated for RBV and its antiviral outcome against RNA
viruses,99,100 however, multiple studies have explained that treat-
ment catastrophe can happen. In the case of RBV, these letdowns
are related to the choice of viral capability augmenting mutations,
executing the intra-host populace absolute over the influence of
lethal mutagenesis projected for RBV. The EASL endorses a tac-
tical lessening of immune system suppression among individuals
with obstinate HEV infection as the first intervention strategy.61
Knowledge gaps
As HEV holds physiognomies of a virus using the “hit-and-run”
approach that supports its genetic evolution. Much exploration is
needed regarding the viral particle structure and its receptor(s)
that should bring some new information on its tissue tropism and
zoonotic spread. Progress in research on contemporary and pre-
sent challenges, like the epidemiological aspects, the standardiza-
tion of diagnostic tests, the clinical control of extrahepatic
indices, the pathogenesis, prevention in populaces at threat, and
the management of chronic hepatitis E may be expedited by anal-
ogous advancement to understand the essential traits of biology
and the medical inquiry of HEV. The molecular detailing of
HEV is insufficient to understand its pathophysiological aspects.
There is a lack of much clinical proof about the causal relation-
ship between HEV and its extrahepatic expressions. Understand-
ing model systems is still pending to gain insights for better
prevention and control. There is an evident gap concerning the
understanding of vaccine safety and efficacy in multi variants
of HEV and immunogenicity of HEV 239 along with knowl-
edge about long-term effectiveness, a period of safety with
less than three doses or smaller interims between doses;
necessity and scheduling of likely promoter dose. There is
also insufficient information related to new lines of treatment
and management options. An information gap exists regarding
efficiency and cost-effectiveness of vaccine program in out-
break scenarios.9,42,47,50,72,84,101,102
Research priorities
Future research is necessary to provide evidence regarding the
causal link between HEV and extrahepatic diseases, their primary
pathogenic mechanisms, assessment of possible management
choices, and the identification of the actual burden of disease etc.
The few salient research areas that can be prioritized to take the
lead over HEV are as follows:
• Sneak into the systematic understanding of critical features of
the HEV life cycle from entry to duplication, assemblage, and
release
• Analyze the biophysical and biochemical configuration of
HEV particles
• Search and study the structural details of the ORF1 poly-
protein (pORF1) and protein ORF3 (pORF3) and ORF4
• Identify and define the crucial host factors and tissue tropism
• Explore pathogenesis involved in HEV-mediated hepatic and
extrahepatic manifestations
• Design the direct-acting or host-targeting antiviral agents
• Study the efficacy and safety of the HEV239 vaccine
• Generate robust cell culture models supporting infection with
all HEV genotypes
• Identify the potential risk areas regarding HEV location among
animals and humans and study the changes and evolution
• Generate epidemiological data regarding prevalence, transmis-
sion, and overall burden of disease and the study of variations
in the curse of infection between or within countries
• Design controllable animal models to study symptoms, innate
immune mechanisms, and associated aspects of immunological
protection
• Identify the alternative procedure for the treatment of patients
that developed an intolerance to current treatment options or
being unresponsive at all
• Explore the screening necessities and risks of HEV among
blood donors, immune-compromised and pregnant women
Conclusion
HEV infection is one of the global health concerns with signifi-
cant morbidity and mortality. It is one of the leading causes of
acute viral hepatitis in developing countries and hepatic failure
among pregnant women. HEV usually occurs in industrialized
regions, mainly having zoonotic transmission. RBV is a drug of
choice in patients suffering from chronic HEV characterized by
prolonged viremia that leads to liver cirrhosis and hepatic failure.
As per current knowledge and recommendations by WHO &
EASL, there are few core essentials to prevent or manage HEV
that includes guaranteeing improved sanitation and access to safe
food and water based on the country context and epidemic
Figure 3 Treatment algorithm for chronic HEV infection (Adapted
from European Association for the Study of the Liver.61)
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dynamics. However, there are much-unanswered research and
clinical inquiries that need to be explored regarding the evidence
for the burden of multiple genotypes of HEV in different geo-
graphical distributions, infection sources, and the data for new
effective HEV-specific antiviral drugs and commercial vaccine
approval.
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